University of Illinois at Chicago, Chicago, Illinois, USA
University of Illinois at Chicago, Chicago, Illinois, USA.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01096-17. Print 2017 Sep.
The nafithromycin concentrations in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) of 37 healthy adult subjects were measured following repeated dosing of oral nafithromycin at 800 mg once daily for 3 days. The values of noncompartmental pharmacokinetic (PK) parameters were determined from serial plasma samples collected over a 24-h interval following the first and third oral doses. Each subject underwent one standardized bronchoscopy with bronchoalveolar lavage (BAL) at 3, 6, 9, 12, 24, or 48 h after the third dose of nafithromycin. The mean ± standard deviation values of the plasma PK parameters after the first and third doses included maximum plasma concentrations () of 1.02 ± 0.31 μg/ml and 1.39 ± 0.36 μg/ml, respectively; times to of 3.97 ± 1.30 h and 3.69 ± 1.28 h, respectively; clearances of 67.3 ± 21.3 liters/h and 52.4 ± 18.5 liters/h, respectively, and elimination half-lives of 7.7 ± 1.1 h and 9.1 ± 1.7 h, respectively. The values of the area under the plasma concentration-time curve (AUC) from time zero to 24 h postdosing (AUC) for nafithromycin based on the mean or median total plasma concentrations at BAL fluid sampling times were 16.2 μg · h/ml. For ELF, the respective AUC values based on the mean and median concentrations were 224.1 and 176.3 μg · h/ml, whereas for AM, the respective AUC values were 8,538 and 5,894 μg · h/ml. Penetration ratios based on ELF and total plasma AUC values based on the mean and median concentrations were 13.8 and 10.9, respectively, whereas the ratios of the AM to total plasma concentrations based on the mean and median concentrations were 527 and 364, respectively. The sustained ELF and AM concentrations for 48 h after the third dose suggest that nafithromycin has the potential to be a useful agent for the treatment of lower respiratory tract infections. (This study has been registered at ClinicalTrials.gov under registration no. NCT02453529.).
37 名健康成年受试者连续 3 天每天口服 800mg 奈福米星,每日 1 次,测定血浆、上皮衬里液(ELF)和肺泡巨噬细胞(AM)中的奈福米星浓度。使用首剂和第 3 剂后 24 小时内采集的系列血浆样本,确定非房室药代动力学(PK)参数的非参数值。每个受试者在第 3 剂奈福米星后 3、6、9、12、24 或 48 小时进行 1 次标准化支气管镜检查和支气管肺泡灌洗(BAL)。首剂和第 3 剂后血浆 PK 参数的均值±标准差分别为:最大血浆浓度(Cmax)为 1.02±0.31μg/ml 和 1.39±0.36μg/ml;达峰时间(Tmax)分别为 3.97±1.30h 和 3.69±1.28h;清除率分别为 67.3±21.3L/h 和 52.4±18.5L/h;消除半衰期分别为 7.7±1.1h 和 9.1±1.7h。根据 BAL 液采样时间的平均或中位数总血浆浓度,奈福米星的 0 至 24 小时血药浓度时间曲线下面积(AUC)(AUC)值为 16.2μg·h/ml。对于 ELF,基于平均浓度和中位数浓度的 AUC 值分别为 224.1 和 176.3μg·h/ml,而对于 AM,基于平均浓度和中位数浓度的 AUC 值分别为 8538 和 5894μg·h/ml。基于 ELF 和总血浆 AUC 值的均值和中位数的穿透率比值分别为 13.8 和 10.9,而基于均值和中位数的 AM 与总血浆浓度的比值分别为 527 和 364。第 3 剂后 48 小时 ELF 和 AM 浓度持续存在,表明奈福米星有可能成为治疗下呼吸道感染的有效药物。(本研究已在 ClinicalTrials.gov 上注册,注册号为 NCT02453529。)